23.66k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The fight against COVID19||+2.07%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||155||+1.57||+1.02%||16:00 GMT-4||9.25M||8.24M||405.24B|
|ABBV||AbbVie Inc.||159.37||+1.45||+0.92%||16:03 GMT-4||4.96M||6.34M||281.84B|
|PFE||Pfizer Inc.||40.8||+0.42||+1.04%||16:03 GMT-4||22.83M||23.08M||229.02B|
|GILD||Gilead Sciences, Inc.||82.97||+1.52||+1.87%||16:00 GMT-4||7.14M||6.25M||104.06B|
|REGN||Regeneron Pharmaceuticals, Inc.||821.67||+10.17||+1.25%||16:00 GMT-4||866.17k||650.92k||89.48B|
|GSK||GlaxoSmithKline plc||35.58||+0.31||+0.88%||16:00 GMT-4||2.79M||3.66M||72.84B|
|MRNA||Moderna, Inc.||153.58||+6.14||+4.16%||16:00 GMT-4||3.78M||3.59M||59.00B|
|TAK||Takeda Pharmaceutical Company Limited||16.48||+0.13||+0.80%||16:00 GMT-4||1.67M||2.68M||51.24B|
|BNTX||BioNTech SE||124.57||+2.00||+1.63%||16:00 GMT-4||803.62k||686.76k||30.23B|
|VIR||Vir Biotechnology, Inc.||23.27||+0.27||+1.17%||16:00 GMT-4||779.89k||1.02M||3.10B|
|NVAX||Novavax, Inc.||6.93||+0.34||+5.16%||16:00 GMT-4||5.23M||6.52M||589.08M|
|INO||Inovio Pharmaceuticals, Inc.||0.82||+0.03||+3.51%||16:00 GMT-4||5.84M||4.50M||204.58M|
Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.
In the last year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a substantial stake in the company which may have...
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) as opportunities that especially stand out. Prosper Junior Bakiny (Axsome Therapeutics): Last year, Axsome Therapeutics' share price doubled, partly due to the FDA approving its depression medicine Auvelity for use. The company's stock is down by 19% since the start of the year.